Docetaxel,Cisplatin,and Fluorouracil (DCF) Regimen for Head,Neck,and Advanced Gastric Cancers

Abstract

The increasing complexity of cancer chemotherapy now requires that pharmacists be familiar with these highly toxic agents. This column will review various issues related to preparation, dispensing, and administration of cancer chemotherapy, and review various agents, both commercially available and investigational, used to treat malignant diseases.

Get full access to this article

View all access options for this article.

References

Janinis

, Papadakou

, Xidakis

. Combination chemotherapy with docetaxel, cisplatin, and 5-fluorouracil in previously treated patients with advanced/recurrent head and neck cancer: a phase II feasibility study. Am J Clin Oncol. 2000; 23(23): 128–131.

Posner

M.R.

, Glisson

, Frenette

. Multicenter phase I-II trial of docetaxel, cisplatin, and fluorouracil induction chemotherapy for patients with locally advanced squamous cell cancer of the head and neck. J Clin Oncol. 2001; 19(4): 1096–1104.

Haddad

, Colevas

A.D.

, Tishler

. Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber Cancer Institute experience. Cancer. 2003; 97(2): 412–418.

Katori

, Tsukuda

, Watai

Comparison of hyperfractionation and conventional fractionation radiotherapy with concurrent docetaxel, cisplatin and 5-fluorouracil (TPF) chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN). Cancer Chemother Pharmacol. 2007; 60(3): 399–406.

Schrijvers

, Van Herpen

, Kerger

. Docetaxel, cisplatin and 5-fluorouracil in patients with locally advanced unresectable head and neck cancer: a phase I-II feasibility study. Ann Oncol. 2004; 15(4): 638–645.

Umeda

, Komatsubara

, Ojima

. Lack of survival advantage in patients with advanced, resectable squamous cell carcinoma of the oral cavity receiving induction chemotherapy with cisplatin (CDDP), docetaxel (TXT) and 5-fluorouracil (5FU). Kobe J Med Sci. 2004; 50(5-6): 189–196.

Vermorken

J.B.

, Remenar

, Van Herpen

. Standard cisplatin/infusional 5-fluorouracil (PF) vs docetaxel (T) plus PF (TPF) as neoadjuvant chemotherapy for nonresectable locally advanced squamous cell carcinoma of the head and neck (LASCCHN): a phase III trial of the EORTC Head and Neck Cancer Groups (EORTC #24971) Proceedings, ASCO 2004 abstract # 5508. (abstract). http://www.asco.org/portal/site/ASCO/template.RAW/menuitem.34d60f5624ba07fd506fe310ee37a01d/?javax.portlet.tpst=0e116779df458209ada2be0aee37a01d_ws_RW&javax.portlet.prp_0e116779df458209ada2be0aee37a01d_viewID=abst_detail_rawview&javax.portlet.begCacheTok=com.vignette.cachetoken&javax.portlet.endCacheTok=com.vignette.cachetoken&index=n&confID=26&abstractID=1556. Accessed March 4, 2008.

Hitt

, Grau

, Lopez-Pousa

. Phase II/III trial of induction chemotherapy (ICT) with cisplatin/5-fluorouracil (PF) vs. docetaxel (T) plus PF (TPF) followed by chemoradiotherapy (CRT) vs CRT for unresectable locally advanced head and neck cancer (LAHNC) (abstract). Proceedings, ASCO 2005 abstract # 5578. http://www.asco.org/portal/site/ASCO/template.RAW/menuitem.34d60f5624ba07fd506fe310ee37a01d/?javax.portlet.tpst=0e116779df458209ada2be0aee37a01d_ws_RW&javax.portlet.prp_0e116779df458209ada2be0aee37a01d_viewID=abst_detail_rawview&javax.portlet.begCacheTok=com.vignette.cachetoken&javax.portlet.endCacheTok=com.vignette.cachetoken&index=n&confID=34&abstractID=32987. Accessed March 4, 2008.

Baghi

, Hambek

, Wagenblast

, May

, Gstoettner

, Knecht

A phase II trial of docetaxel, cisplatin and 5-fluorouracil in patients with recurrent squamous cell carcinoma of the head and neck (SCCHN). Anticancer Res. 2006; 2(1B): 585–590.

10.

Chiarion-Sileni

, Corti

, Ruol

. Phase II trial of docetaxel, cisplatin and fluorouracil followed by carboplatin and radiotherapy in locally advanced oesophageal cancer. Br J Cancer. 2007; 96(3): 432–438.

11.

Vermorken

J.B.

, Remenar

, van Herpen

. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med. 2007; 357(17): 1695–1704.

12.

Posner

M.R.

, Hershock

D.M.

, Blajman

C.R.

. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med. 2007; 357(17): 1705–1715.

13.

Park

S.R.

, Chun

J.H.

, Kim

Y.W.

. Phase II study of low-dose docetaxel/fluorouracil/cisplatin in metastatic gastric carcinoma. Am J Clin Oncol. 2005; 28(5): 433–438.

14.

D.Y.

, Kim

T.Y.

, Kwon

J.H.

. Docetaxel + 5-fluorouracil + cisplatin 3-day combination chemotherapy as a first-line treatment in patients with unresectable gastric cancer. Jpn J Clin Oncol. 2005; 35(7): 380–385.

15.

Van Cutsem

, Moiseyenko

V.M.

, Tjulandin

. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 2006; 24(31): 4991–4997.

16.

Sadighi

, Mohagheghi

M.A.

, Montazeri

, Sadighi

Quality of life in patients with advanced gastric cancer: a randomized trial comparing docetaxel, cisplatin, 5-FU (TCF) with epirubicin, cisplatin, 5-FU (ECF). BMC Cancer. 2006; 6(12): 274.

17.

Ajani

J.A.

, Moiseyenko

V.M.

, Tjulandin

. Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study Group. J Clin Oncol. 2007; 25(12): 3205–3209.

18.

Ajani

J.A.

, Moiseyenko

V.M.

, Tjulandin

. Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: the V-325 Study Group. J Clin Oncol. 2007; 25(22): 3210–3216.

19.

Roth

A.D.

, Fazio

, Stupp

. Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research. J Clin Oncol. 2007; 25(22): 3217–3223.

20.

Comprehensive Cancer Network. NCCN Clinical Practice Guidelines - Head and neck cancers. V.1.2007. http://www.nccn.org/professionals/physician_gls/PDF/head-and-neck.pdf. Accessed September 20, 2007.

21.

Comprehensive Cancer Network. NCCN Clinical Practice Guidelines - Gastric Cancer. V.2.2007. Accessed September 20, 2007.

22.

Cohen

M.R.

, Smetzer

1999 (2 June). Preparing for a damaging medication error. ISMP Medication Safety Alert! Vol 4 (No. 14).

23.

Savarese

, Taplin

M.E.

, Halabi

, Hars

, Kreis

, Vogelzang

A phase II study of docetaxel (Taxotere), estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: preliminary results of cancer and leukemia group B Trial 9780. Semin Oncol. 1999; 26(5 suppl 17): 39–44.

24.

Hesketh

P.J.

, Kris

M.G.

, Grunberg

S.M.

. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol. 1997; 15(1): 103–109.

25.

National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines - Antiemesis. V.2.2008. http://www.nccn.org/professionals/physician_gls/PDF/antiemesis.pdf. Accessed January 20, 2008.

26.

Kris

M.G.

, Hesketh

P.J.

, Somerfield

M.R.

. American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol. 2006; 24(35): 2932–2947.

27.

Multinational Association for Supportive Care in Cancer. Antiemetic Guidelines. 2007. http://www.mascc.org/media/Resource_centers/MASCC_Guidelines_Update.pdf. Accessed January 20, 2008.

28.

Kris

M.G.

, Gralla

R.J.

, Clark

R.A.

. Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin. J Clin Oncol. 1985; 3(10): 1379–1384.

29.

Geling

, Eichler

H.G.

Should 5-Hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J Clin Oncol. 2005; 23(6): 1289–1294.

30.

Terrey

J.P.

, Aapro

M.S.

The activity of granisetron in patients who had previously failed ondansetron antiemetic therapy. Eur J Clin Res. 1996; 8: 281–288.

31.

Carmichael

, Keizer

H.J.

, Cupissol

, Milliez

, Scheidel

, Schindler

A.E.

Use of granisetron in patients refractory to previous treatment with antiemetics. Anticancer Drugs. 1998; 9(5): 381–385.

32.

de Wit

, de Boer

A.C.

, vd Linden

G.H.

, Stoter

, Sparreboom

, Verweij

Effective cross-over to granisetron after failure to ondansetron, a randomized double blind study in patients failing ondansetron plus dexamethasone during the first 24 hours following highly emetogenic chemotherapy. Br J Cancer. 2001; 19: 85(8): 1099–1101.

33.

Smith

I.E.

A dose-finding study of granisetron, a novel antiemetic, in patients receiving cytostatic chemotherapy. The Granisetron Study Group. J Cancer Res Clin Oncol. 1993; 119(6): 350–354.

34.

Soukop

A dose-finding study of granisetron, a novel antiemetic, in patients receiving high-dose cisplatin. Granisetron Study Group. Support Care Cancer. 1994; 2(3): 177–183.

35.

Cornelison

T.L.

, Reed

Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormaplatin. Gynecol Oncol. 1993; 50(2): 147–158.

36.

Kintzel

P.E.

Anticancer drug-induced kidney. Drug Saf. 2001;24(1): 19–38.

37.

Taxotere [package insert]. Aventis Pharmaceuticals, Inc., Bridgewater, NJ, 2005.

38.

Zanotti

K.M.

, Markman

Prevention and management of antineoplasticinduced hypersensitivity reactions. Drug Saf. 2001; 24(10): 767–779.

39.

Smith

T.J.

, Khatcheressian

, Lyman

G.H.

. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol. 2006; 24(19): 3187–3205.

40.

National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology - Myeloid Growth Factors. V.1.2008. http://www.nccn.org/professionals/physician_gls/PDF/myeloid_growth.pdf. Accessed January 20, 2008.

41.

Larson

D.L.

Treatment of tissue extravasation by antitumor agents. Cancer. 1982; 49(9): 1796–1799.

42.

Larson

D.L.

What is the appropriate management of tissue extravasation by antitumor agents?

Plast Reconstr Surgery. 1985; 75(3): 397–405.

43.

Mullin

, Beckwith

M.C.

, Tyler

L.S.

Prevention and management of antineoplastic extravasation injury. Hosp Pharm. 2000; 35(1): 57–74.

44.

Benson

3rd , Ajani

J.A.

, Catalano

R.B.

. Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol 2004;22(14): 2918–2926.

45.

Kintzel

P.E.

, Dorr

R.T.

Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function. Cancer Treat Rev. 1995; 21(1): 33–64.

46.

Aronoff

G.R.

, Bennett

W.M.

, Berns

J.S.

. Drug Prescribing in Renal Failure. 5th ed. Philadelphia, PA: American College of Physicians: 2007.

47.

Bruno

, Hille

, Riva

. Populations pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol. 1998; 16(1): 187–196.

48.

Floyd

, Mirza

, Sachs

, Perry

M.C.

Hepatotoxicity of chemotherapy. Semin Oncol. 2006; 33(1): 50–67.

49.

King

P.D.

, Perry

M.C.

Hepatotoxicity of chemotherapy. Oncologist. 2001; 6(2): 162–176.